Press releases
- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
- Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.466 |
---|---|
High | 0.47 |
Low | 0.4658 |
Bid | 0.3902 |
Offer | 0.55 |
Previous close | 0.47 |
Average volume | 6.83k |
---|---|
Shares outstanding | 180.67m |
Free float | 168.37m |
P/E (TTM) | -- |
Market cap | 87.70m USD |
EPS (TTM) | -0.2367 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 12:05 BST.
More ▼